1. This Month in Gastroenterology
Laura Harrell, Eugene B. Chang 
Gastroenterology 
Volume 130, Issue 2, Pages (February 2006)
DOI: /j.gastro
Copyright © 2006 American Gastroenterological Association Terms and Conditions

2. Figure 1
Percentage of patients in each adalimumab dose group and the placebo group achieving remission at weeks 1, 2, and 4 (*P = .001 vs placebo).
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2006 American Gastroenterological Association Terms and Conditions

3. Figure 2
Increased CHI3L1 expression in human IBD. A–F Immunohistochemical analysis of the expression of CHI3L1 is shown A objective, 20×; B–F objective, 40×). Colonic tissue obtained from normal individual (A and B), Crohn’s disease (C and D), and ulcerative colitis (E and F) patients were stained with rabbit anti-human CHI3L1 (A–C, E and F) or normal rabbit serum D.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2006 American Gastroenterological Association Terms and Conditions

4. Figure 3
Dipeptidyl peptidase IV (DPPIV)-mutant F344 rat model to study liver repopulation by transplanted cells isolated from ED14 fetal rat liver. Isolated wild type cells are infused into the liver through the portal vein into DPPIV- mutant rats and their fate, proliferation, and morphologic appearance monitored by enzyme histochemistry or immunohistochemistry for DPPIV. Cells that have differentiated into hepatocytes are shown in the left inset and cells that have differentiated into cholangiocytes are shown in the right inset.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2006 American Gastroenterological Association Terms and Conditions